Therefore 81% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned "Buy" rating on Tuesday, June 20 by Leerink Swann. They set a "buy" rating and a $90.00 price objective for the company. As per Thursday, September 24, the company rating was initiated by Oppenheimer.

Sage Therapeutics, Inc. (NASDAQ:SAGE) reported its EPS in the last quarter as $-1.88/Share lagging the analyst estimate of $-1.67/Share by a difference of $-0.21. Sage Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $96.99.

In related news, CFO Kimi Iguchi sold 4,000 shares of Sage Therapeutics stock in a transaction dated Thursday, November 17th. In this case performance of tends to percentage rate of return for a stock for a given time frame. According to this momentum indicator, a reading above 70 suggests the stock is entering overbought territory and that the recent uptrend may be about to reverse. The firm earned "Buy" rating on Thursday, November 2 by Stifel Nicolaus. The stock traded within a range of $85.25 and $96.99. Insider ownership during the a year ago has decreased by a net of 2.37 million shares. Schwab Charles Investment Management Inc. increased its position in Sage Therapeutics by 1.2% during the first quarter. It has outperformed by 99.75% the S&P500.

Investors sentiment decreased to 0.98 in Q2 2017. Its down 0.13, from 1.11 in 2017Q1. Great Point Partners Llc sold 248,400 shares as Sage Therapeutics Inc (Put) (SAGE)'s stock rose 0.86%. There were 30 sold out positions, amounting to 374,478 shares. The Fund's investments include semiconductor devices, advertising and marketing, life science equipment, exploration and production, commercial mortgage-backed securities, insurance brokers, communications equipment, electrical power equipment, food and drug stores, corporate bonds and notes, residential mortgage-backed securities, asset-backed securities, corporate bank debt, other common stocks and electrical components. Following the completion of the sale, the chief financial officer now directly owns 75,739 shares in the company, valued at $3,921,008.03.

On 9/15/2017, RBC Capital released a statement for SAGE Therapeutics (NASDAQ:SAGE) bumped up the target price from $0.00 to $117.00 that suggested an upside of 0.81%. Susquehanna Intl Group Llp has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Royal Bank Of Canada upped their price objective on shares of Sage Therapeutics to $145.00 and gave the company an "outperform" rating in a report on Thursday. 541 are held by Federated Pa. Bridgeway Mgmt holds 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 93,300 shares. Da Davidson & Co stated it has 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Victory Capital Management invested 0.08% in SAGE Therapeutics Inc (NASDAQ:SAGE). The insider, STARR KEVIN P, now holds 1.09 million shares of SAGE. California Employees Retirement System reported 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

SAGE Therapeutics, Inc.is a clinical-stage biopharmaceutical company. The company has market cap of $3.58 billion. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. It now has negative earnings. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

Turtle Beach Corporation is an audio technology company. The company has market cap of $27.23 million. DekaBank Deutsche Girozentrale now owns 16,950 shares of the biopharmaceutical company's stock valued at $497,000 after buying an additional 3,100 shares during the period. About 400,589 shares traded or 119.97% up from the average.